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Introduction 
Liver cell adenomas (LCA) are benign tumors that oc- 
cur primarily in women with a history of oral contracep- 
tive use. While rare, LCA are clinically important 
because of their propensity for sudden, unpredictable 
hemorhage or malignant transformation. Differentia- 
tion from focal nodular hyperplasia or hepatocellular 
carcinoma may be difficult even with sophisticated im- 
aging modalities. Current management guidelines are 
based on the presence or absence of symptoms, the 
certainty of diagnosis, and the response, if any, to with- 
drawing putative growth stimuli. Complete excision, 
sparing as much normal liver as possible, is generally 
recommended, except in patients with adenomatosis. 
This may require anatomical resection (either 
lobectomy or segmentectomy), local wedge excision, or 
enucleation. Rarely, orthotopic liver transplantation 
may be required in patients with large, centrally placed 
lesions, recurrence following previous resection(s), or 
adenomatosis. Nonsurgical ablation techniques such as 
interstitial radio-frequency or laser hyperthermia and 
cryotherapy may also be useful in selected patients. 
Discussion 
Benign liver tumors are fairly common, with an esti- 
mated autopsy incidence of 1% or 2%. 1 Those encoun- 
tered most frequently in clinical practice include 
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hemangioma, focal nodular hyperplasia (FNH), and 
liver cell adenoma (LCA). Hemangiomas differ from 
FNH and LCA in many respects. They are congenital 
rather than neoplastic in origin, and there are no well 
documented reports of malignant transformation. Com- 
pared to FNH and LCA, which are solid tumors, 
hemangiomas are composed microscopically of dilated 
vascular sinuses lined with endothelium. Increase in 
diameter over time occurs in a minority of patients 
and is usually not associated with the onset or worsen- 
ing of symptoms. Reports of significant enlargement 
during pregnancy or in patients taking oral contracep- 
tives are largely anecdotal, suggesting that the growth of 
hemangiomas may not be entirely hormone-dependent. 
A definitive diagnosis can be made with 90% sensitivity 
and accuracy with either magnetic resonance imaging 
(MRI) or single-photon emission computed tomo- 
graphy (SPECT), using technetium 99m-labeled red 
blood cells. 2 Based on these observations, many centers 
now advocate conservative therapy, and limit surgery to 
patients with incapacitating symptoms or life-threaten- 
ing complications. 3,4 When surgery is indicated, enucle- 
ation is preferred to formal hepatic resection, and can 
be accomplished safely with minimal disturbance of 
liver function and preservation of normal functioning 
parenchyma/, 6 
FNH and LCA are separate and distinct benign le- 
sions that differ in etiology, morphology, and natural 
history. Unfortunately, treatment dilemmas occur with 
some regularity because FNH and LCA may be indis- 
tinguishable based on clinical, pathologic, and radio- 
graphic features. 
Patients with LCA are generally women of 
childbearing age with a history of oral contraceptive 
use. Little was known about these unusual tumors until 
1973, when Baum published a landmark paper estab- 
lishing a clear association betwen oral contraceptives 
and the development of LCA. 7 We have since learned 
that LCA arising in oral contraceptive users tend to be 
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larger and are associated with higher rates of intra- 
tumoral and intraperitoneal hemorrhage that those oc- 
curring in nonusers. 8 Additional risk factors include 
androgenic steroids, Type Ia glycogen storage disease, 
and insulin-dependent diabetes mellitus. Dietary 
therapy aimed at correcting abnormal levels of insulin, 
glucagon, and glucose in patients with LCA and Type Ia 
glycogen storage disease may result in tumor regression, 
suggesting that insulin and/or glucagon may be putative 
growth stimuli. 
Although the populations of patients developing 
LCA and FNH are similar, there is a lower correlation 
with oral contraceptive use in patients with FNH. The 
mode of presentation also differs for the two lesions. 
Nearly 90% of FNH cases are discovered incidentally at 
autopsy, during operations for unrelated indications, or 
on routine physical examination. 9,1~ Patients with FNH 
may complain of chronic, nonspecific upper abdominal 
discomfort, but rarely present with acute symptoms or 
abdominal findings. In contrast, up to 80% of patients 
with LCA are symptomatic. 8-1~ Of these patients, one- 
half present with symptoms related to mass effect (pain, 
early postprandial satiety, etc), and the remainder 
present with symptoms dur to tumor rupture or hemor- 
rhage. 8 Constant or premonitory symptoms are uncom- 
mon among patients with acute symptoms and rarely 
aid in establishing a preoperative diagnosis. 
Among patients with ruptured LCA there is a wide 
spectrum of presentation and treatment. Spontaneous 
intratumoral hemorrhage may cause acute right upper 
quadrant pain that mimics biliary colic. LCA are prone 
to bleed because they consist of multiple sinusoids of 
thin-walled capillaries supplied by arterial blood under 
high pressure. In addition, they contain little connective 
tissue support, which allows blood to disperse exten- 
sively throughout the tumor? ~ Nearly two-thirds of 
patients presenting with acute abdominal pain and 
hypotension require emergency surgery to control 
bleeding? 2 In this setting, the average mortality rate is 
approximately 6%, but rates approaching 20% have 
been reported. 12,13 While the size of an adenoma gener- 
ally predicts the likelihood of hemorrhage, the severity 
of bleeding does not necessarily correlate with the size 
of the tumor. The remainding one-third of patients de- 
velop stable hematomas and can be monitored short- 
term in an intensive care unit setting. One should not be 
lulled into a false sense of security in these patients if 
hemorrhage ceases spontaneously and the lesion ap- 
pears stable on CT or ultrasound. Because of the sud- 
den and unpredictable threat of repeated hemorrhage, 
all patients with acutely symptomatic LCA should 
ultimately undergo some definitive form of surgical 
treatment. 
Treatment dilemmas arise chiefly because of the diffi- 
culty in distinguishing LCA from other benign liver 
tumors and from primary or metastatic liver cancer. 
Biochemical liver function tests are not helpful. 
Ultrasonographic features are nonspecific and CT has a 
low positive predictive value that precludes routine 
clinical use. 14 The limited efficacy of US and CT may be 
partly explained by the fact that these lesions exhibit 
imaging characteristics that are similar to those of nor- 
mal surrounding hepatic parenchyma. Characteristic 
findings such as a stellate scar (FNH) and intralesional 
hemorrhage or necrosis (LCA) are distinctly uncom- 
mon. Angiography accurately defines hepatic vascular 
anatomy but lacks specificity. 15 Nuclear scintigraphy 
with technetium-labelled sulfur colloid has been used to 
differentiate LCA from FNH, based on the premise that 
FNH, which contains cells, will selectively take up iso- 
tope and appear as a "hot" area, while LCA, which do 
not contain cells, will appear as a void or filling defect. 
However, scintigraphic and pathologic data from one 
recent retrospective study of 13 proven cases of LCA 
demonstrated histologic evidence of cells in all cases, 
and uptake of technetium-99m sulfur colloid in 3 cases 
(23 %).15 Conversely, focal defects can be demonstrated 
in approximately 30% of patients with proven FNH. 1~ 
Isotope scans are further limited because the voids 
thought to be characteristic of LCA can also occur with 
primary or metastatic liver cancer and hemangiomas. 
At present no single radiologic modality has sufficient 
specificity to be diagnostic in this setting. CT and, more 
recently, MR provide descriptive information regarding 
the number and location of lesions and may suggest the 
diagnosis of FNH or LCA based on the presence of a 
central avascular scar and intratumoral hemorrhage or 
necrosis, respectively. In our experience and that of 
others, scintigraphy should also be obtained to provide 
data relevant to diagnosis and treatment. In general, a 
solitary mass that exhibits normal or increased uptake 
of radio-colloid will prove to be FNH, especially if iden- 
tified in an asymptomatic young woman without liver 
disease. Complementary findings of homogeneity and/ 
or slight hypodensity and lack of intratumoral hemor- 
rhage on CT and hypervascularity with an intense cap- 
illary stain on angiography will help to confirm the 
diagnosis of FNH and should be sufficient for clinical 
management in the absence of histopatholgy. 
FNH has a benign prognosis and can be managed 
conservatively in asymptomatic patients once the diag- 
nosis has been established with reasonable certainty. 
Progression of symptoms or development of complica- 
tions in patients treated expectantly is extremely un- 
common. When indicated, excision can be safely 
recommended, with minimal reported operative mor- 
tality and morbidity. 1~ Following successful excision of 
FNH, patients can be reassured that recurrence is un- 
likely even if they resume oral contraceptives or be- 
come pregnant. 
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Patients with suspected or proven LCA require a 
different strategy. The majority of acutely symptomatic 
patients will require excision, frequently in the absence 
of a hisopathologic diagnosis. In asymptomatic patients, 
recommendations regarding excision versus expectant 
therapy are colored by concerns regarding potential 
malignant transformation to carcinoma. Unfortunately 
there is remarkably little information regarding the 
natural history of unresected LCA. In a recent review of 
the literature, Foster and Berman 16 identified only five 
instances of probable transformation from LCA to can- 
cer, including four patients taking oral contraceptives at 
the time of diagnosis. Despite cessation of oral contra- 
ceptives and apparent tumor stabilization or regression, 
all patients developed cancer within 2-7 years. They 
also analyzed descriptions of 22 additional patients with 
single or multiple LCAs that were either biopsied or 
incompletely resected and followed for periods ranging 
from 3 months to 10 years. Tumor involution occurred 
in eight of nine patients (89%) following cessation of 
oral contraceptives, one patient underwent resection 
for tumor regrowth, and none of the patients experi- 
enced rupture or developed cancer. 
The risk of transformation from LCA to cancer has 
traditionally been viewed as a compelling argument for 
excision, tempered partially be the risks of major he- 
patic resection, especially in young, healthy, and other- 
wise aymptomatic patients. This risk may be somewhat 
overstated but is arguably real and cannot be dis- 
counted. Given the decreased risk of hepatic resection 
when performed by skilled and experienced surgeons, 
most experts now recommend resection of all solitary 
LCA, even if they involute following cessation of oral 
contraceptives. Patients with large central tumors or 
multiple tumors who undergo incomplete resection 
must be followed for decades with serial imaging studies 
and should abstain indefinitely from oral contracep- 
tives, anabolic steroids, and other putative growth 
stimuli. Serial measurements of alfa-fetoprotein may be 
helpful in detecting malignant change. 16 
Multiple adenomas occur in 12%-30% of patients 
and present special surgical problems. 9,1~ Children with 
Type I or III glycogen storage disease and patients re- 
ceiving androgenic steroids are prone to develop mul- 
tiple LCA with attendant risks of hemorrhage or 
malignant transformation. Adenomatosis is rare disor- 
der characterized by the occurrence of multiple (>10) 
adenomas in the liver, Adenomatosis and liver cell 
adenoma differ in many important chracteristics and 
may, therefore, represent distinct entities. 9,~7 There is 
no female predominance in adenomatosis and oral con- 
traceptives are generally not implicated as etiologic 
factors. In addition, intratumoral or intraperitoneal 
hemorrhage, which occurs with both conditions, may 
be more common with adenomatosis. The lesions of 
adenomatosis vary in size from 0.5 to >10cm, are 
distributed uniformly throughout both lobes of the 
liver, and histologically consist of unencapsulated ag- 
gregations of small-sized hepatocytes that contain no 
portal triads. 17 In patients presenting with acute hemor- 
rhage, surgery should consist of enucleation or 
resectional debridement, sparing as much normal pa- 
renchyma as possible. Spontaneous malignant transfor- 
mation has been demonstrated in at least one patient 5 
years after the original diagnosis of adenomatosis. 9 In 
view of this malignant potential, adenomatosis should 
perhaps be considered as an indication for liver trans- 
plantation. However, the rarity of the complication may 
not justify this aggressive an approach. 
The surgical approach to LCA has evolved consider- 
ably over the past several decades. Despite advances in 
radiologic imaging and nuclear scintigraphy, accurate 
differentiation of LCA from other bengin or malignant 
liver lesions may be difficult. In patients with acute 
symptoms of intratumoral or intraperitoneal hemor- 
rhage, surgical intervention is warranted in all cases, 
regardless of whether the bleeding ceases spontane- 
ously. Increase in tumor size, indeterminate diagnosis, 
and progression of mass-related symptoms are 
additional indications for surgical excision. Until 
recently, formal hepatic resection was considered a 
hazardous procedure, with reported mortality rates of 
4 %-20 % .18-20 The maj or causes of perioperative mortal- 
ity associated with hepatic resection are uncontrollable 
hemorrhage or injury to the blood supply or biliary 
ducts supplying the unresected segments of liver. There 
is a also strong correlation between operative blood 
loss and the incidence and severity of postoperative 
complications. 
Formal hepatic resection is currently a safe procedure 
with minimal mortality and complication rates of 
<10%. 9'11'21 Several factors have contributed to im- 
proved results, including a better understanding of liver 
anatomy, expanded use of intraoperative ultras- 
onography, and technical refinements that facilitate 
controlled hepatic resection with minimal blood loss. 
Based on prior studies of hepatic anatomy, we now 
understand that the liver can be functionally divided 
into eight segments based on the distribution of the 
portal pedicles and the location of the hepatic veins. 
Each of these segments can theoretically be resected 
while maintaining the integrity of the remaining seg- 
ments72 This classification provides the surgeon with a 
powerful tool and is a prerequisite for performing safe 
liver surgery. Increased availability and familiarity with 
intraoperative ultrasound, especially B-mode or real- 
time scanning, allows the surgeon to precisely identify 
internal vascular architecture, identify unsuspected pa- 
thology, and plan sectoral or segmental resections based 
on portal and hepatic venous structures. Useful infor- 
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mation that alters operative strategy can be obtained in 
up to 30% of patients using this technology. 23 
Two distinct techniques of liver resection have been 
described. Resection with primary vascular control was 
first described by Lortat-Jacob and colleagues in the 
early 1950s 24 and consists of ligating and dividing portal 
pedicles and draining hepatic veins before transecting 
the parenchyma. Advantages include reduction of 
bleeding and sharp demarcation of the devascularized 
portion of liver to be resected. The major disadvantage 
is massive and often uncontrollable bleeding from a 
torn hepatic vein or the vena cava and the attendant 
potential for air embolism. An alternative approach, 
popularized by Bismuth, 22 consists of temporary inflow 
occlusion combined with primary parenchymal 
transection in the plane of lobar division. Using this 
technique, the portal elements and hepatic veins are 
secured as they traverse the plane of dissection within 
the substance of the liver. Primary parenchymal dissec- 
tion reduces the potential risk of injury to inflow or 
outflow vessels, but may be associated with increased 
bleeding and usually requires either partial or total vas- 
cular exclusion of the liver. 
Hepatic vascular exclusion facilitates resection in pa- 
tients with large or posterior tumors, in whom the risk 
of massive bleeding or air embolism is appreciable. This 
technique was originally described by Heaney and 
Jacobson in 197525 and has been summarized recently in 
an excellent article by Huguet et al. a6 This approach 
entials clamping of the portal inflow vessels and the 
inferior vena cava above and below the liver prior to 
parenchymal transection. Accessory or replaced hepatic 
arteries must be identified and clamped to prevent 
troublesome bleeding from the plane of dissection. Oc- 
cluding clamps are placed in a specific order to minimize 
hepatic venous congestion: portal pedicle followed by 
infrahepatic and suprahepatic portions of the inferior 
vena cava, respecitvely. Following resection, the 
infrahepatic vena cava clamp is partially released to aid 
in identifying vessls along the cut surface of the liver 
that might require suture ligation. The suprahepatic and 
portal pedicle clamps are then removed, and the 
perihepatic space is drained widely with silicone drains 
exited through the side or flank. 
The efficacy and safety of hepatic vascular exclusion 
have been documented in serveral recent series with 
excellent metabolic tolerance of the liver for periods of 
up to l h. a7,28 Significant reduction of intraoperative 
bleeding, associated coagulation problems, and postop- 
erative complications have been reported using this 
techniqueY Data from our institution indicates that the 
use of this technique markedly decreases intraoperative 
blood loss in patients who undergo resection or enucle- 
ation of liver cell adenomas. 29 One must keep in mind 
that attention to technical details is critical for achieving 
total vascular exclusion. Improper positioning of the 
caval clamps or failure to identify an accessory or re- 
placed hepatic artery will lead to hepatic venous conges- 
tion, troublesome bleeding that impairs visualization of 
the operative field, and possible hemodynamic compro- 
mise for the patient. When used properly, this technique 
reduces operative blood loss and the health risks associ- 
ated with blood transfusion. 
Formal hepatic resection may not be necessary once 
the histopathologic diagnosis of LCA has been con- 
firmed and the specter of malignancy has been dis- 
pelled. This is especially important, since features of 
LCA and hepatocellular carcinoma can occasionally 
coexist within the same lesion. 9 Most single adenomas 
can be enucleated, even those located posteriorly or 
within the substance of the liver. The major decision is 
whether to employ partial (inflow) occlusion or total 
vascular exclusion prior to enucleation. Enucleation of 
hepatic hemangiomas has been well described, is both 
safe and effective, and has largely replaced hepatic re- 
section for treatment of these benign tumors2 ,6 The 
technique is relatively straightforward. Once vascular 
control has been achieved, the liver capsule is incised 
several millimeters beyond the periphery of the tumor. 
A cleavage plane or sheath of compressed liver tissue 
that defines the border between the hemangiomatous 
tissue and the normal liver is easily defined and guides 
further dissection, using either the surgeon's finger or 
the ultrasonic aspirator. We prefer to use the ultrasonic 
aspirator, which aids in identifying and skeletonizing 
major bile ducts and vascular structures for careful liga- 
tion and division. Careful dissection in the cleavage 
plane maintains a relatively bloodless field and facili- 
tates complete removal of the tumor. Once the tumor 
has been enucleated, the resulting defect can be man- 
aged by external catheter drainage alone or combined 
with mobilization of a flap of vascularized omentum to 
obliterate the cavity. Enucleation is equally applicable 
to all benign tumors of the liver and has already been 
used sucessfully for treatment of patients with liver cell 
adenomas59 This technique is particularly useful for 
patients with two or three adenomas in whom formal 
resection would sacrifice an excessive amount of normal 
parenchyma. In addition to being useful for benign liver 
tumors, enucleation has also been used successfully to 
treat hydatid cysts of the liver? ~ 
In addition to formal hepatic resection and enucle- 
ation, other forms of surgical therapy are also available 
to treat benign tumors o f  the liver. Interstitial 
hyperthermia employing radiofrequency electrocautery 
has been used successfuly to treat one patient with an 
LCA who refused more traditional treatment?~ The 
extent of necrosis induced by the needle is exactly pre- 
dictable based on the size of the needle, the tempera- 
ture of the needle tip, and the exposure time. The 
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p rocedure  can be accomplished laparoscopical ly  and  is 
mos t  useful  for per iphera l ly-s i tua ted  lesions. However ,  
based  on  exper ience  with thermal  ab la t ion  of hepato-  
cellular  cancers,  deeper  adenomas  should  be safely 
accessible with u l t r asound  guidance.  32 Cryoab la t ion  has 
also b e e n  used successfully to t reat  L C A ,  and  ma y  be 
especially useful  for central ly  loca ted  tumors  that  
would  otherwise  requi re  t r i s e g m e n t e c t o m y )  3 Final ly ,  
o r tho topic  l iver t r ansp lan ta t ion  ( O L T )  may  be neces-  
sary in symptomat ic  pat ients  with potent ia l ly  life- 
t h rea t en ing  complicat ions  if t u m o r  size o r  loca t ion  
prec lude  safe resect ion,  or if pr ior  resec t ion  has failed to 
control  symptoms.  O L T  will rarely be n e e d e d  for be- 
n ign  liver lesions. In  one  series of 3239 pa t ients  unde r -  
going OLT,  only 12 pat ients  (0.37%) requ i red  
t r ansp l an t a t i on  for benign,  symptomat i c  neoplasms.  33 
The  indica t ions  for O L T  in five of the six a d e n o m a  
pat ients  who requi red  u rgen t  t r ansp l an t a t i on  inc luded  
sus ta ined growth and  recur ren t  i n t r a tumora l  or in t rap-  
e r i tonea l  hemorrhage .  Long- t e rm ou t come  fol lowing 
O L T  was excellent ,  with a repor ted  m e d i a n  survival  of 
88 months .  Whi le  seemingly  extreme,  O L T  may  be the 
t r e a t m e n t  of choice for large, l i fe - threa ten ing  ben ign  
tumors  that  prec lude  more  conven t iona l  forms of 
t rea tment .  
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